Canopy Growth Brings Canadian Medical Cannabis Flower to UK Patients
Key Points
- Canopy Growth Corporation will supply four Canadian-grown medical cannabis flower strains for distribution in the United Kingdom.
- GROW Group U.K. Ltd. will distribute the products under Canopy Growth’s Spectrum Therapeutics medical cannabis brand.
- The agreement marks the first launch of Canopy Growth’s portfolio products in the UK market.
- Canopy Growth said its renewed EU Good Manufacturing Practice certification supports its ability to supply medical cannabis products across Europe.
Canopy Growth Corporation (NASDAQ: CGC) announced plans to expand its European medical cannabis business by supplying four Canadian-grown flower strains to the United Kingdom. GROW Group U.K. Ltd., a manufacturer and distributor of prescribed cannabis-based medicines in Europe, will commercialize the products in the UK under Canopy Growth’s Spectrum Therapeutics brand.
Four Canadian-Grown Medical Cannabis Strains Will Reach UK Patients
The initial launch will introduce four Canadian-grown medical cannabis flower strains from Canopy Growth’s portfolio into the UK market.
Products will be supplied to GROW Group, which will distribute them as prescribed cannabis-based medicines under the Spectrum Therapeutics medical brand. Canopy Growth described the move as the introduction of its portfolio products to the UK.
Canopy Growth Uses EU GMP Supply Capability to Support UK Expansion
The company said its UK supply plans build on the recent renewal of EU Good Manufacturing Practice, or EU GMP, certification at its Kincardine, Ontario cultivation facility.
Certification supports the company’s ability to supply medical cannabis products to markets across Europe. Chief Executive Officer Luc Mongeau said Canopy Growth sees continued opportunity to expand its European medical cannabis business as demand grows across the region.
Spectrum Therapeutics Will Lead Canopy Growth’s UK Medical Cannabis Launch
The four cannabis flower strains will be sold in the UK under Spectrum Therapeutics, Canopy Growth’s global medical cannabis brand.
Canopy Growth said the partnership combines its Canadian-grown cannabis supply with GROW Group’s ability to commercialize prescribed cannabis-based medicines in the UK and other European markets.
Canopy Growth Continues Building International Medical Cannabis Business
The UK launch is part of Canopy Growth’s broader strategy to expand the international reach of its Canadian-grown cannabis products.
The company said it is focused on disciplined expansion into attractive European medical cannabis markets while using its cultivation, quality, regulatory, and supply capabilities to serve patients, consumers, and partners.
